Phaseline

Targets › DGK

DGK (Deoxyguanosine kinase, mitochondrial): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Infectious disease; next expected readout Oct 2027.

Phosphorylates deoxyguanosine and deoxyadenosine in the mitochondrial matrix, with the highest efficiency for deoxyguanosine. In non-replicating cells, where cytosolic dNTP synthesis is down-regulated, mtDNA synthesis depends solely on DGUOK and TK2. (UniProt, Q16854)

Open in Phaseline: the race on DGK, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
CellSight Technologies[18F]F-AraG
Radiolabeled substrate for deoxyguanosine kinase (dGK) and deoxycytidine kinase (dCK), bot
DGK, DCKPhase 2Covid19Oct 2027

Conditions

Covid19 (1)

Modalities

small molecule (1)

Companies

CellSight Technologies (1)

Related targets

DCK (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.